Q&A: Novo Nordisk marketing chief aims to change the conversation around obesity, even as society has its own plans
Novo Nordisk consumer marketing chief Mark Materacky wants to change the conversation around obesity. And with Wegovy, the first new anti-obesity med approval in a decade — with good efficacy and safety data — Novo seems well positioned to do that.
However, in the year and a half since its approval, Wegovy, or semaglutide for weight loss, a cascade of events has marred the way.
Type 2 diabetes meds, including semaglutide, marketed for diabetes treatment under the brand Ozempic, and tirzepatide, sold as Mounjaro by Eli Lilly, started getting picked up by new online telehealth companies, along with personal physicians who realized the meds could be prescribed off-label for obesity and weight loss.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.